George Mason University
Exploratory Proteomic Analysis of Transgenic Alzheimer’s Disease Mouse Model Treated with Young Blood Plasma
Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid plaques and tau tangles. Studies suggest that treatment using young blood plasma in transgenic AD mice is associated with enhanced synaptic activity, increases in neuronal proteins, and behavioral improvements. This exploratory proteomic study used liquid chromatography–mass spectrometry (LCMS) to analyze the composition of blood plasma for the identification of proteins that may contribute to synaptic and behavioral changes. Plasma samples were collected from AD-type (rTg4510 h-Tau P301/CaMKII) and wild-type (WT) mice treated with saline or young blood plasma. A bottom-up approach was used to identify proteins by assessing fragmentation output from LC-MS and cross-referencing values with validated mouse protein databases. 4 proteins were significantly differentiated between AD plasma and AD saline groups including up-regulation of MDH2 and down-regulation of KNG1, KCNB1, and KRT15. Pathway analysis of these results suggest disruptions in brain energy metabolism and blood coagulation may induce chronic immune activation that coincide with AD progression. This study also reveals the need for additional research on blood coagulation mechanisms and its involvement in AD as well as a potential biomarker for diagnosis. By targeting these specific proteins and downstream pathway, future studies may gain a better understanding of the molecular mechanisms that underlie AD.
Author and committee
dc:creator, dc:contributor.*- Author
-
- Petrie, Allison
Subjects
dc:subject × 6Identifiers
dc:identifier.*- Identifier
- hdl:1920/13642
- OAI identifier oai:identifier
- oai:MARS:1920/13642